Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | IL1B | P01584 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | F13A1 | P00488 | 1/20 | 0.32 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
| ▸ | TGM1 | P22735 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22397886 | 0.87 | IL1B (0.34) | IL1B | |
| SCHEMBL20936959 | 0.86 | NR1H2 (0.38) | USP30GPR119SYKIL1BF13A1 | |
| SCHEMBL23523211 | 0.86 | NR1H2 (0.38) | USP30GPR119SYKIL1BF13A1 | |
| SCHEMBL29501570 | 0.86 | NR1H2 (0.38) | USP30GPR119SYKIL1BF13A1 | |
| SCHEMBL22397923 | 0.86 | USP30 (0.34) | USP30SSTR4GPR119JAK3SPR | |
| SCHEMBL22398073 | 0.84 | USP30 (0.33) | USP30SSTR4GPR119JAK3SPR | |
| SCHEMBL22398005 | 0.82 | GPR119 (0.36) | USP30GPR119JAK3SPR | |
| SCHEMBL20936735 | 0.81 | PTPN2 (0.39) | USP30GPR119F13A1TGM2TGM1 | |
| SCHEMBL23523399 | 0.80 | NR1H2 (0.43) | GPR119JAK3SPR | |
| SCHEMBL23957013 | 0.80 | NR1H2 (0.43) | GPR119JAK3SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3703680-B1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNIV VANDERBILT (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11352344-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352344-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200339547-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2020-10-29 | — | — | US | disclosed |
| US-20200339547-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2020-10-29 | — | — | US | disclosed |
| EP-3703680-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2020-09-09 | — | — | EP | disclosed |
| CN-111565718-A | Antagonists of muscarinic acetylcholine receptor M4 | 范德比尔特大学 | 2020-08-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339547-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM2, CHRM3, CHRM4 | USP30 3134/4885SSTR4 353/4885GPR119 88/4885 |
| US-11352344-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM2, CHRM3, CHRM4 | USP30 3338/4885SSTR4 331/4885GPR119 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.